Merck & Co in advanced talks for acquisition season and aiming to agree to a purchase For the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could cost around $40 billion or more.
The people said the companies are discussing a price above $200 per share for Cezanne and seeking to seal a deal on or before Merck’s quarterly earnings announcement scheduled for July 28. Seasoned shares closed at $175.13 on Wednesday.